A phase I‐II clinical trial of the anti‐CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.
M Haran, V Mirkin, A Braester… - British Journal of …, 2018 - search.ebscohost.com
M Haran, V Mirkin, A Braester, N Harpaz, O Shevetz, M Shtreiter, S Greenberg, O Mordich…
British Journal of Haematology, 2018•search.ebscohost.comThe article discusses a patient-centered phase I-II clinical protocol of milatuzumab combined
with comfort care in elderly patients with refractory chronic lymphocytic leukemia (CLL), who
were not eligible for any other form of treatment. Topics covered include patient
characteristics and response to milatuzumab treatment, the most common significant
adverse event, and the effect of milatuzumab on apoptosis.
with comfort care in elderly patients with refractory chronic lymphocytic leukemia (CLL), who
were not eligible for any other form of treatment. Topics covered include patient
characteristics and response to milatuzumab treatment, the most common significant
adverse event, and the effect of milatuzumab on apoptosis.
Abstract
The article discusses a patient-centered phase I-II clinical protocol of milatuzumab combined with comfort care in elderly patients with refractory chronic lymphocytic leukemia (CLL), who were not eligible for any other form of treatment. Topics covered include patient characteristics and response to milatuzumab treatment, the most common significant adverse event, and the effect of milatuzumab on apoptosis.
search.ebscohost.com
